Specific programme: Joint Programming Initiative funded through ERA-MIN 3 Cofund 2022 programme and AEI “Proyectos de Cooperación Internacional” (Proyecto PCI2023-143369, financiado por MCIN/AEI/10.13039/501100011033 y por la Unión Europea).

APCIN code: PCI2023-143369

UPV/EHU Partner Status: Beneficiary

UPV/EHU PI: Rafael Morales

Project start: 01/10/2023
Project end:   30/09/2026
 

Brief description: NanoCANdi develops new functional materials and biosensing microtechnology for cancer diagnosis. The project designs and manufactures large magnetic moment nanostructures with unique spin configurations for biomedical applications, specifically optimized for ultra-high sensitive giant magnetoresistance biosensors by micromagnetic modelling of both nanostructures and sensors. It addresses a key strategy in the fight against cancer: the early-stage detection of the disease. A crucial feature in this strategy is the specific biorecognition of cancer indicators. NanoCANdi undertakes this key point creating exclusive aptamers for a precise immobilization of cancer biomarkers, developing an innovative aptakiss/aptaswitch selection approach. The project expands new technologies and materials, producing biosensing devices that will impact the healthcare system with the adoption of precise medicine, letting physicians to detect and monitor treatments with reliable and affordable biochips.